Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Molecular staples shape a cancer killer

03.09.2004


Howard Hughes Medical Institute (HHMI) researchers have successfully designed and improved a new type of cancer-killing compound by performing molecular surgery to stabilize the molecule so that it selectively triggers cell death.



The idea for developing the compound emerged from the HHMI laboratory of Stanley J. Korsmeyer, who leads one of the hottest research teams currently studying programmed cell death, or apoptosis, a genetic program that executes cells that are no longer needed. Using the biologically active portion of a protein that triggers apoptosis, Korsmeyer’s team successfully inserted non-natural amino acids into the peptide sequence and then performed a chemical reaction that created a "staple" within the molecule, resulting in its stabilization. Korsmeyer and the paper’s lead author, Loren D. Walensky, who are at the Dana-Farber Cancer Institute at Harvard Medical School, reported their studies in the September 3, 2004, issue of the journal Science.

The chemical approach they applied, called hydrocarbon stapling, was developed by their collaborator Gregory L. Verdine of Harvard University, and permitted the researchers to overcome the tendency of short peptides to lose their critical three-dimensional structure – and their ability to kill cells -- when removed from the context of the complete protein. This has been one of the greatest obstacles associated with using short peptides as therapeutic agents, and has hindered their legitimacy as pharmaceutical lead compounds. By making the peptides more resistant to degradation and enabling their cellular uptake, the hydrocarbon staple overcomes classic shortcomings of peptide therapeutics.


As the molecular events that lead to execution and death have become clearer during the last decade, researchers speculated that it would not be long before biotechnology and pharmaceutical companies were racing to develop novel compounds that could be used to hasten or prevent the demise of cells. "Academic and industrial laboratories are engaged in a Herculean effort to develop new molecules that reactivate the apoptotic program in tumor cells," wrote HHMI investigator Steven F. Dowdy of the University of California, San Diego, in a Perspectives article that was published in the same issue of Science.

Korsmeyer, Walensky, and their colleagues aimed to construct a key regulatory segment of an apoptosis-triggering protein called BID that could induce apoptosis in cancer cells. Their objective was to create a short peptide that functionally mimicked the specific region of the BID protein that elicits cell death. Theoretically, such a small molecule -- basically a short string of amino acids -- could insinuate itself into cancer cells to trigger their suicide. "Our goal was to modify the natural peptide sequence only enough to stabilize or reinforce its shape to improve its pharmacological properties," said Walensky. The researchers used the hydrocarbon stapling strategy to brace the peptide from within.

"We substituted non-natural amino acids for natural amino acids in selected positions," he said. "The non-natural amino acids look very similar to the natural ones, except that they include hydrocarbons that can be cross-linked to one another. This cross-linking provides a constraint, which doesn’t allow the peptide to unfold." The researchers dubbed the engineered peptide "stabilized alpha-helix of BCL-2 domains" (SAHB). The BCL-2 family of proteins regulates apoptosis.

When the researchers examined SAHB’s properties, they found that it assumed a stable alpha-helical shape, bound to the right protein to trigger apoptosis, and resisted degradation by proteases. They also found that SAHB specifically triggered the cell’s power plants, the mitochondria, to release a protein that participates in launching apoptotic destruction.

Their experiments with leukemia cells cultured in the laboratory revealed that SAHB could enter, and, more importantly, inhibit the growth of those cells. "When we saw that we could activate cell death in a specific way in whole cells, we were eager to conduct animal studies," said Walensky. So, the researchers tested the effects of SAHB on mice that harbored human leukemia cells. "We found that SAHB treatment effectively suppressed leukemia in these mice," he said.

According to Walensky, the experiments are the first steps in a broader effort to construct hydrocarbon-stapled alpha-helical peptides that affect many control points of apoptosis. These are necessary because different cancers may have thwarted the apoptotic machinery in different ways, he said. "The goal would be to use the natural sequences of these pro-apoptotic peptides to try to specifically activate the cell death program in a resistant cell," said Walensky. "For example, certain lymphomas are specifically driven by BCL-2 overexpression. So, if you could knock down some of the impact of that BCL-2, you would tip that lymphoma cell over the edge toward death."

Korsmeyer, Walensky, and their colleagues are now developing and testing different hydrocarbon-stapled BH3 domains against a range of cancer cells. Ultimately, they believe that further development of these peptides could broaden the arsenal of compounds used to kill different cancers.

Walensky said he would not be surprised to see hydrocarbon stapling of alpha-helices applied to control many interactions between proteins. "The alpha-helix plays a pivotal role in many biological interactions," said Walensky. "So if we could target protein-protein interactions at critical biological control points using the natural, evolutionarily derived sequence for that protein target -- with just this minor modification of hydrocarbon stapling -- then we might have a whole new set of tools to study and manipulate protein interactions within cells."

Jennifer Michalowski | EurekAlert!
Further information:
http://www.hhmi.org

More articles from Life Sciences:

nachricht How molecules teeter in a laser field
18.01.2019 | Forschungsverbund Berlin

nachricht Discovery of enhanced bone growth could lead to new treatments for osteoporosis
18.01.2019 | University of California - Los Angeles

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Ten-year anniversary of the Neumayer Station III

The scientific and political community alike stress the importance of German Antarctic research

Joint Press Release from the BMBF and AWI

The Antarctic is a frigid continent south of the Antarctic Circle, where researchers are the only inhabitants. Despite the hostile conditions, here the Alfred...

Im Focus: Ultra ultrasound to transform new tech

World first experiments on sensor that may revolutionise everything from medical devices to unmanned vehicles

The new sensor - capable of detecting vibrations of living cells - may revolutionise everything from medical devices to unmanned vehicles.

Im Focus: Flying Optical Cats for Quantum Communication

Dead and alive at the same time? Researchers at the Max Planck Institute of Quantum Optics have implemented Erwin Schrödinger’s paradoxical gedanken experiment employing an entangled atom-light state.

In 1935 Erwin Schrödinger formulated a thought experiment designed to capture the paradoxical nature of quantum physics. The crucial element of this gedanken...

Im Focus: Nanocellulose for novel implants: Ears from the 3D-printer

Cellulose obtained from wood has amazing material properties. Empa researchers are now equipping the biodegradable material with additional functionalities to produce implants for cartilage diseases using 3D printing.

It all starts with an ear. Empa researcher Michael Hausmann removes the object shaped like a human ear from the 3D printer and explains:

Im Focus: Elucidating the Atomic Mechanism of Superlubricity

The phenomenon of so-called superlubricity is known, but so far the explanation at the atomic level has been missing: for example, how does extremely low friction occur in bearings? Researchers from the Fraunhofer Institutes IWM and IWS jointly deciphered a universal mechanism of superlubricity for certain diamond-like carbon layers in combination with organic lubricants. Based on this knowledge, it is now possible to formulate design rules for supra lubricating layer-lubricant combinations. The results are presented in an article in Nature Communications, volume 10.

One of the most important prerequisites for sustainable and environmentally friendly mobility is minimizing friction. Research and industry have been dedicated...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Our digital society in 2040

16.01.2019 | Event News

11th International Symposium: “Advanced Battery Power – Kraftwerk Batterie” Aachen, 3-4 April 2019

14.01.2019 | Event News

ICTM Conference 2019: Digitization emerges as an engineering trend for turbomachinery construction

12.12.2018 | Event News

 
Latest News

Additive manufacturing reflects fundamental metallurgical principles to create materials

18.01.2019 | Materials Sciences

How molecules teeter in a laser field

18.01.2019 | Life Sciences

The cytoskeleton of neurons has been found to be involved in Alzheimer's disease

18.01.2019 | Health and Medicine

VideoLinks
Science & Research
Overview of more VideoLinks >>>